J&J Closes $1B Firefly Deal; Gilead, Amgen Advance EU Bids

Johnson & Johnson ($JNJ) completed its acquisition of Firefly Bio for $1 billion in cash, gaining access to the company's proprietary Firelink degrader antibody conjugate platform designed to target KRAS-driven and other difficult-to-treat solid tumors. The company also proposed a $5.5 billion settlement to resolve tens of thousands of ovarian cancer talc lawsuits, a decade-long legal dispute that requires majority claimant approval to proceed. $JNJ closed at $265.53, up 3.9% recently, reflecting positive momentum ahead of the settlement decision. The Firefly transaction expands Johnson & Johnson's oncology portfolio with next-generation targeted therapy capabilities.

Amgen ($AMGN) received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for an expanded Repatha indication to reduce cardiovascular risk in high-risk adults without prior heart attack or stroke, based on Phase 3 data showing significant reduction in major adverse cardiovascular events. Gilead Sciences ($GILD) secured a positive CHMP opinion for expanding Trodelvy's use alongside Keytruda in certain advanced triple-negative breast cancer patients. $GILD shares have delivered a 5.07% 30-day return and 9.15% year-to-date gain, with a five-year total shareholder return of 130.07%. Pfizer ($PFE) and BioNTech won European Commission marketing authorization for their XFG-adapted COVID-19 vaccine for individuals aged 6 months and older across all EU member states for the 2026-2027 season.

Amgen ($AMGN) closed at $387.42, down 1.44%, despite delivering a 93.9% return over the past five years, with discounted cash flow models pointing to meaningful upside while market multiples appear closer to fair value. Merck ($MRK) closed at $130.36, down 1.11%, after more than doubling with a 102% total return over five years, though recent intrinsic value estimates show a sizeable DCF gap versus current share price while broader valuation checks remain mixed. Gilead Sciences ($GILD) traded at $132.73 after delivering a 130.1% return over five years, with its HIV franchise growing 8% and patent protection extending through 2036. Abbott Laboratories ($ABT) met quality investing criteria with 8.42% revenue growth and 19.34% return on invested capital, alongside near-perfect cash conversion.

Align Technology will add three new independent directors to its board and launch a review of its operations following discussions with activist investor Elliott Investment Management. The new board members will be selected for expertise in healthcare technology, medical devices, global operations, and scaling high-growth businesses. Elliott has increasingly focused on healthcare companies over the past year, often pushing for board representation and strategic reviews to improve performance.

Regeneron Pharmaceuticals ($REGN) is scheduled to report earnings Thursday before the market opens. Humana ($HUM) indicated that 2026 performance is tracking in line with expectations, with management emphasizing planned Medicare Advantage margin expansion in 2027, progress in its Stars program, and continued operating-cost reductions as key components toward a sustainable pretax margin. The European regulatory decisions for $AMGN and $GILD await final European Commission approval following the positive CHMP opinions.